- Live market news
- Stocks
- LLY
Eli Lilly and Company
LLYStockUSA
Eli Lilly and Company
Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 36 countries. Its products are marketed in approximately 90 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.
The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so.
Latest news on LLYranked by Oyticker for market impact
- 65Impact
Type 2 Diabetes Market Expansion Driven by GLP-1 Agonists and Novel Therapies Through 2036
Global type 2 diabetes market projected to grow steadily through 2036, supported by rising prevalence, obesity trends, and adoption of next-generation therapies including GLP-1 receptor agonists, SGLT2 inhibitors, and emerging dual/triple incretin agents from major pharma players.
NVOLLYPharmaceuticalsHealthcareBiotechnology - 25Impact
LLY to present 21 dermatology data presentations at Fall Clinical 2026
Eli Lilly announced 21 presentations of dermatology portfolio data at the 2026 Fall Clinical Dermatology Conference, signaling continued R&D activity in chronic skin conditions.
LLYPharmaceuticalsBiotechnology - 72Impact
Lilly's Jaypirca gains FDA approval for treatment-naïve CLL/SLL patients
Eli Lilly announced FDA approval of an expanded indication for Jaypirca (pirtobrutinib) in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), extending the non-covalent BTK inhibitor's addressable market.
LLYPharmaceuticalsOncologyBiotechnology - 72Impact
Lilly's Foundayo shows cardiovascular safety with sustained glycemic and weight benefits in Phase 3 ACHIEVE-4
Eli Lilly announced Phase 3 ACHIEVE-4 trial results for Foundayo (orforglipron), an oral GLP-1 agonist, demonstrating cardiovascular safety alongside A1C reduction and weight loss in type 2 diabetes. This represents the company's largest and longest study of the candidate.
LLYPharmaceuticalsBiotechnologyHealthcare - 72Impact
Lilly's EloraTZP combo shows superior weight loss and glycemic control vs. tirzepatide monotherapy in Phase 2b
Eli Lilly reported that EloraTZP (eloralintide + tirzepatide combination) achieved greater weight loss and A1C reduction compared to tirzepatide 15 mg monotherapy in adults with obesity and type 2 diabetes. This positions a potential next-generation dual-mechanism therapy ahead of competitors in the GLP-1/GIP space.
LLYPharmaceuticalsBiotechnology - 35Impact
Four biotech stocks identified with near-term catalysts
A financial publication highlights four biotechnology companies—NTHI, CNTB, VBIO, and LLY—as having strong upcoming catalysts, though specific catalyst details are not disclosed in the available excerpt.
VBIONTHILLYCNTBBiotechnologyPharmaceuticalsHealthcare - 62Impact
Lilly's EBGLYSS meets Phase 3b endpoints in hand/foot atopic dermatitis
Eli Lilly announced that lebrikizumab (EBGLYSS) monotherapy met primary and secondary efficacy endpoints at Week 16 in a Phase 3b trial for moderate-to-severe hand and foot atopic dermatitis, showing rapid improvements in skin clearance, pruritus, pain and patient satisfaction.
LLYPharmaceuticalsBiotechnology - 35Impact
Lilly launches Change the Course Commitment for diabetes/obesity access in LMICs
Eli Lilly announced a new global health initiative targeting treatment gaps in diabetes and obesity across low- and middle-income countries. The program represents a corporate social responsibility and market-access strategy in high-growth emerging markets.
LLYPharmaceuticalsHealthcare - 35Impact
FDA approves Lilly's Olumiant for pediatric severe alopecia areata
Eli Lilly received FDA approval for Olumiant (baricitinib) in pediatric patients aged 12+ with severe alopecia areata, expanding the drug's addressable population beyond adults.
LLYPharmaceuticalsDermatology
What LLY filed
- 29 Oct 2026
- 29 Oct 2026
- 5 Aug 2026
- 5 Aug 2026
- 20 May 2026
From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.